{"schema":"hottub-news/story/v1","story":"st_xb3a257hsornhijqpeia","title":"Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer","title_en":null,"outlets":1,"brief":null,"page":"https://hottub.news/stories/lantheus-announces-first-patient-dosed-in-sparrow-phase-2-3-xb3a257hso","count":1,"items":[{"id":"n_xb3a257hsornhijqpeia","seq":419243,"kind":"press_release","title":"Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer","url":"https://www.globenewswire.com/news-release/2026/09/28/3369814/0/en/lantheus-announces-first-patient-dosed-in-sparrow-phase-2-3-registrational-trial-in-prostate-cancer.html","summary":"Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancer Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancer","published":"2026-09-28T12:00:00Z","seen":"2026-09-28T12:07:22Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","nasdaq:lnth","us5165441032"],"entities":[{"id":"Q109828878","name":"Sparrow","type":"event"},{"id":"Q181257","name":"prostate cancer","type":"other"}],"mentions":2,"story":"st_xb3a257hsornhijqpeia","category":"health","category_p":0.5600000023841858,"sentiment":"neutral","tone":0.2199999988079071,"political":0.05999999865889549}]}